Emerging Growth Biotech Stocks
Tag: Biotech
A niche company in biotech could prove to be the biggest...
Recently trading at around .70 per share, PetVivo Holdings, Inc. (OTCQB: PETV) just announced something interesting on Tuesday which brought a $1.40 share price and what could be the beginning of a strong accumulation of their stock.
Can B Corp. (OTCQB: CANB) Partners with Dr. Karl Zarse to...
Miami, FL –October 22, 2020, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for...
Stocks to Own in October
The writer also likes Facebook (NYSE: FB) citing the stock is cheap, being around 14% below its august highs. But with the largest hater of tech, (Elizabeth Warren) potentially coming into some great power if Biden should pull out a win, I would stay cautiously away from big tech as her plans could include break up’s of companies like FB.
Cannabics Pharmaceuticals (CNBX) Prepares to Submit the FDA with a pre-IND...
Cannabics Pharmaceuticals (CNBX) Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33
Stocks that are most Vulnerable to a Biden Victory
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
Why InflaRx (IFRX) Could Piggyback Off Regeneron’s Sudden Interest
After the initial deadly volley from the novel coronavirus, the broader healthcare industry’s attention shifted from developing treatments to researching and developing vaccines. Not...
PAO Group, Inc. (PAOG) FDA Application Process For Respiratory Cannabis Drug...
PAO Group, Inc. (PAOG) FDA Application Process For Respiratory Cannabis Drug Treatment Update Scheduled This Friday
Throw $5,000.00 into any of these Coronavirus Vaccine Stocks
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
MATEON’S (MATN) PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST...
MATEON’S (MATN) PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA
Arizona State University/Halberd (HALB) Initiate Patent Application for Unique New Engineered...
Arizona State University/Halberd (HALB) Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody